Stock INBX INHIBRX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Inhibrx, Inc.

Equities

INBX

US45720L1070

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
34.14 USD -0.15% Intraday chart for Inhibrx, Inc. -1.61% -10.16%
May. 24 Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi MT
May. 09 Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi
MT
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
PR
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
PR
Inhibrx : Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Form 8-K
PU
Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
BU
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
PR
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX
PR
Inhibrx Shares Fall After Q4 Net Loss Widens
MT
Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $1.6M
MT
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
PR
Inhibrx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Inhibrx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
BU
Arecor Therapeutics hails Arestat as 2023 performance "strong"
AN
Sanofi bets $1.7b on potential best-in-class rare disease therapy
AQ
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
AQ
North American Morning Briefing : S&P 500 Futures Point to Fresh Record on Netflix Results
DJ
Health Care Flat After J&J Earnings -- Health Care Roundup
DJ
Arecor pleased as investee Inhibrx sells therapy to Sanofi
AN
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INBX Stock
  4. News Inhibrx, Inc.